Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection

Completed

• Conditions: Cardiovascular Diseases; SARS; Cardiovascular Risk Factor

• Registration Number: NCT04327479
• Lead Sponsor: University Hospital, Essen

Brief Summary

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infects host-cells via ACE2-receptors, which leads to pneumonia (COVID-19) but also can lead to myocarditis (acute myocardial injury) and chronic damage to the cardiovascular system. Therefore, cardiovascular protection may be necessary when treating patients with COVID-19 infection. This may especially be necessary in patients with cardiovascular diseases, risk factors, and co-medication.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-03-26
• Study First Submitted: 2020-03-26
• Study First Submitted QC: 2020-03-26
• Study First Posted: 2020-03-31
• Primary Completion: 2022-03-25
• Study Completion: 2022-07-25
• Status Verified: 2022-11
• Last Update Submitted: 2022-11-02
• Last Update Posted: 2022-11-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 728

Inclusion Criteria

• Patients with suspected SARS-CoV2/Covid-19 infection

Exclusion Criteria

• Unwillingness to participate

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
All-cause mortality	During 1 year follow-up	mortality of any cause

Secondary Outcome Measures

Name	Time	Method
Major adverse cardiovascular events	During 1 year follow-up	Myocardial infarction, stroke, or CV death
30-day mortality	Within 30 days after inclusion	mortality of any cause

Trial Locations

Locations (1)

University Hospital Essen; 🇩🇪 Essen, NRW, Germany